-
Loading metrics
Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability
- Paul Germonpré,
- Tim Van den Wyngaert
![PLOS](/resource/img/logo-plos.png)
x
- Published: April 11, 2019
- https://doi.org/10.1371/journal.pone.0215135